Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases-Reference-Cited by-同舟云学术

Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases

Published:2014-03 Issue:5 Volume:50 Page:1035-1037
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Ieni A.,Barresi V.,Giuffrè G.,Caltabiano R.,Cascone A.,Del Sordo R.,Cabibi D.,Zeppa P.,Lanzafame S.,Sidoni A.,Franco V.,Tuccari G.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference11 articles.

1. Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases;Aitken;Ann Oncol,2010

2. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer: a meta-analysis;Chen;Breast Cancer Res Treat,2012

3. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases;Hoefnagel;Cancer,2012

4. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis;Curtit;Oncologist,2013

5. Experts’ opinion: recommendations for retesting breast cancer metastases for HER2 and hormone receptor status;Penault-Llorca;Breast,2013

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer;Frontiers in Oncology;2022-06-23

2. Biomarker discordance between primary breast cancer and bone or bone marrow metastases;Japanese Journal of Clinical Oncology;2019-02-22

3. Letter to the Editor regarding the paper by Park et al., Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1);European Journal of Cancer;2017-04

4. HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach;Disease Markers;2015

5. Discordance Rate of HER2 Status in Primary Gastric Carcinomas and Synchronous Lymph Node Metastases: A Multicenter Retrospective Analysis;International Journal of Molecular Sciences;2014-12-03